drugset / Trial / NCT00005629

Vaccine Therapy in Treating Patients With Liver Cancer

NCT00005629

Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.

Timeline

Start
1999-07
Primary completion
2002-05
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AFP gene hepatocellular carcinoma vaccine Vaccine 100 ug Other
Subject AFP gene hepatocellular carcinoma vaccine Vaccine 500 ug Other
Subject AFP gene hepatocellular carcinoma vaccine Vaccine 1000 ug Other
Background incomplete Freund's adjuvant Other / unclassified 2 ml Other

Indications